secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001398733-26-000016
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive posts Q4 net loss of $31.9M; Anaphylm resubmission delayed to Q3 2026
-------------------------------------------------------------------------------

- Q4 revenue $13.0M (+10% YoY); net loss $31.9M ($0.26/share) incl $13.6M legal; excl legal net loss $18.7M.
- Full year 2025 revenue $44.5M (down 23% YoY); net loss $83.8M ($0.78/share) incl $14.3M legal; cash $121.2M.
- FY2026 guidance: revenue $46-50M, Non-GAAP adjusted EBITDA loss $35-30M, year-end cash target $70M.
- RTW amendment extends Anaphylm deadline to June 30, 2027; warrant for 375k shares at $4; RTW commits $5M stock purchase.
- Anaphylm CRL in Jan 2026; NDA resubmission planned Q3 2026 after Type A FDA meeting within 30 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/0001398733-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001398733-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer